Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Comment by 2b7f6fabon Oct 05, 2022 6:49am
175 Views
Post# 35006009

RE:The 2nd PP

RE:The 2nd PP
Cash on hand was running low.  The delays caused by the over hyped pandemic consumed cash that might have taken us through Ph2.  I think it prudent to raise money long before your bank account hits zero.  $5 million might cover the next twelve months cash burn.  The recently extended warrants and those warrants expiring in January if exercised would bring in another $3.2 million.  The warrants from these current PPs if exercised brings in another $7 million.  If my math is correct that's $15 million while only issuing approx 27 million more shares.  That seems like a better deal than the $15 million for 57 million shares that was raised a few years back.  I for one won't wait till the end to exercise my warrants assuming an appropriate rise in stock price occurs from BTD, AA or vaccine.  Extending existing warrants is a way of rewarding those shareholders that have helped to support the company all these years, jmho.  Add a couple million more for stock options and it would seem like enough cash to get the other two indications up and running.

Keep in mind the accumulated deficit on the financials at the end of 2021 was only $53 million.  Big pharma spends that much running their cafeterias each year.
<< Previous
Bullboard Posts
Next >>